Johnson & Johnson (NYSE:JNJ) Q3 2023 Earnings Conference Call October 17, 2023 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joe Wolk - Executive Vice President, Chief Financial Officer John Reed - Executive Vice President, Pharmaceuticals, R&D Joaquin Duato - Chairman and Chief Executive Officer Erik Haas - Vice President, Litigation Ahmet Tezel - Innovative Medicine and MedTech R&D Conference Call Participants David Risinger - Leerink Partners Matt Miksic - Barclays Ch ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_460873ef3df8e32961495fd4f39fb3b3.html ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_914f5589be1172d38b36f0e185df44f5.html ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_6069736f33e4c9f17cfb4166fbfa408c.html ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended July 2, 2023 or Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☐ for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State or other jurisdiction of (I.R.S. Emp ...

Johnson & Johnson (NYSE:JNJ) Q2 2023 Earnings Conference Call July 20, 2023 8:30 AM ET Company Participants Jessica Moore - Vice President of Investor Relations Joaquin Duato - Chairman and Chief Executive Officer Joe Wolk - Executive Vice President, Chief Financial Officer Erik Haas - Worldwide Vice President of Litigation Conference Call Participants Larry Biegelsen - Wells Fargo Vamil Divan - Guggenheim Securities Joanne Wuensch - Citibank Chris Schott - JPMorgan Trung Huynh - Credit Suisse Terence Flynn ...

2nd Quarter 2023 Earnings Call Cautionary Note on Forward-looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on ...

Johnson & Johnson (NYSE:JNJ) Goldman Sachs 44th Annual Global Healthcare Conference Call June 13, 2023 4:20 PM ET Company Participants Biljana Naumovic - Worldwide Vice President, Oncology Mark Wildgust - Medical Affairs Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Here we are. And welcome back from lunch, everybody. I hope everyone enjoyed that last panel discussion. Always informative to hear from the dark side. The opportunity now is to have the afternoon session kick off. ...

Johnson & Johnson (NYSE:JNJ) Bernstein's 39th Annual Strategic Decisions Conference 2023 May 31, 2023 10:00 AM ET Company Participants Joaquin Duato - CEO & Chairman Conference Call Participants Lee Hambright - Sanford C. Bernstein & Co. Lee Hambright Okay. We are live. Great. Thank you. So everybody, I'm Lee Hambright, U.S. medical device analyst at Bernstein. We are thrilled to host Johnson & Johnson, Chairman and CEO, Joaquin Duato. Thanks so much for being here. We're scheduled for a 50-minute fireside ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended April 2, 2023 or Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☐ for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State or other jurisdiction of (I.R.S. Em ...